KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Merck (MRK) Deferred Taxes (2016 - 2026)

Merck has reported Deferred Taxes over the past 18 years, most recently at -$315.0 million for Q1 2026.

Quarterly Deferred Taxes fell 69.35% to -$315.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.8 billion through Mar 2026, down 30.06% year-over-year, with the annual reading at -$1.7 billion for FY2025, 33.79% down from the prior year.
Deferred Taxes was -$315.0 million for Q1 2026 at Merck, up from -$825.0 million in the prior quarter.
Over five years, Deferred Taxes peaked at -$51.0 million in Q1 2024 and troughed at -$931.0 million in Q4 2023.
The 5-year median for Deferred Taxes is -$336.0 million (2023), against an average of -$394.2 million.
Year-over-year, Deferred Taxes tumbled 66000.0% in 2022 and then soared 81.59% in 2024.
A 5-year view of Deferred Taxes shows it stood at -$307.0 million in 2022, then plummeted by 203.26% to -$931.0 million in 2023, then soared by 33.83% to -$616.0 million in 2024, then plummeted by 33.93% to -$825.0 million in 2025, then soared by 61.82% to -$315.0 million in 2026.
Per Business Quant, the three most recent readings for MRK's Deferred Taxes are -$315.0 million (Q1 2026), -$825.0 million (Q4 2025), and -$212.0 million (Q3 2025).